Overview

Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Q3week carboplatin with weekly abraxane and trastuzumab as neoadjuvant therapy in resectable and unresectable HER2+ (stage IIa-IIIb) breast cancer
Phase:
Phase 2
Details
Lead Sponsor:
William Sikov
William Sikov MD
Collaborator:
Yale University
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Trastuzumab